Target intelligence / Profile preview

Descending pain modulatory system (DPMS)

Target
DPMS
Molecular classification
Neural pathway, Other
01

Overview

The descending pain modulatory system (DPMS) is a complex neural network that regulates the transmission of nociceptive information from the periphery to the brain. Centered in the midbrain periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM), this system projects to the spinal cord dorsal horn to either inhibit (antinociception) or facilitate (pro-nociception) pain signals. It utilizes various neurotransmitters, most notably endogenous opioids, serotonin, and norepinephrine, to adjust the gain of the pain experience based on emotional, cognitive, and environmental contexts. In chronic pain conditions such as fibromyalgia or neuropathic pain, the DPMS often becomes dysfunctional, characterized by a loss of inhibitory control or an increase in descending facilitation, contributing to central sensitization. Pharmacological therapies like opioids and antidepressants (SNRIs and TCAs) target this system by enhancing descending inhibition, thereby providing systemic analgesia. Because the DPMS is a multi-component physiological pathway rather than a single molecular target, it serves as a broad framework for multi-modal pain management strategies.

Other names
Descending inhibitory pain pathwayDescending pain control systemEndogenous pain modulatory systemPAG-RVM-spinal cord axisDescending inhibitory system
02

Mechanism of action

Activation of descending inhibitory pathways via mu-opioid receptors in the periaqueductal gray and rostral ventromedial medulla, and enhancement of spinal norepinephrine and serotonin levels via reuptake inhibition to strengthen top-down pain control.

03

Biological functions

Nociception modulationAntinociceptionPain facilitationSensory processingHomeostasis
04

Disease associations

Chronic painNeuropathic painFibromyalgiaMigraineComplex regional pain syndromeCentral sensitization
05

Safety considerations

Opioid-induced hyperalgesiaTolerance and physical dependenceSerotonin syndrome risk with polypharmacyNonspecific systemic side effects of SNRIs/TCAs
06

Interacting drugs

Morphine

7 more in the full profile.

07

Biomarkers

Conditioned pain modulation (CPM) efficiencyfMRI BOLD signaling in the periaqueductal gray (PAG)Diffuse noxious inhibitory control (DNIC) response

Beyond the preview

Go deeper on Descending pain modulatory system (DPMS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Descending pain modulatory system (DPMS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call